organization · Reporting owner
Redmile Biopharma Investments II, L.P.
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Absci CorpABSI · Entity 4685 | Director · 10% owner | July 21, 2021 | July 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Absci Corp
Report date July 21, 2021 · Filed July 22, 2021
Jointly reported with Redmile Group, LLC, Green Jeremy
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series E Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2021-07-21 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Series E convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the holder's election, or automatically upon the closing of the Issuer's initial public offering, in each case based on a pre-stock split conversion price of $19.6166 per share. On July 19, 2021, the Issuer effected a one-for-3.3031 forward stock split of its common stock. The Series E convertible preferred stock has no expiration date. F5: These securities are directly owned by a private investment vehicle managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicle. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (collectively with the private investment vehicle, the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Reporting Persons are a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security | IndirectSee Footnotes | Not disclosed |
Reported balance
Holding disclosure · report date 2021-07-21 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The Convertible Promissory Note dated as of March 17, 2021 (the "Note") will automatically convert, upon the first of the following transactions to occur, into: (i) shares of the Issuer's common stock upon a qualified initial public offering ("IPO") or a qualified merger with a Special Purpose Acquisition Issuer ("SPAC"); or (ii) shares of the Issuer's preferred stock in the event of a qualified equity financing in which the Issuer raises gross proceeds of $30 million or more through sale of preferred stock. The Note is also convertible into shares of the Issuer's capital stock issued in a non-qualifying financing transaction upon the election of the Reporting Persons (as defined below). F3: The Note is convertible at a conversion price equal to the lower of (i) a per share price equal to 82% of the per share price paid by the new investors in such qualified financing, IPO or SPAC transaction or (ii) the price per share calculated on the basis of a pre-money valuation of the Issuer of $1.5 billion divided by the aggregate number of shares of common stock of the Issuer deemed outstanding on an as-converted, fully diluted basis including (a) all shares reserved under the Issuer's stock option plan and (b) 50% of additional shares reserved in connection with any expansion of the option pool as a result of the transaction, as of immediately prior to such qualified financing, public offering, or conversion event ("Cap Price"). F4: In the event of a non-qualified financing, the Note is convertible at the Cap Price. In the event of a deemed liquidation event, the outstanding balance may be converted into that number of shares of a new series of preferred stock of the Issuer at the Cap Price. On or after the maturity date of the Note, at the option of the Reporting Persons, the outstanding balance may be converted into that number of shares of a new preferred stock of the Issuer at the Cap Price. F5: These securities are directly owned by a private investment vehicle managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicle. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (collectively with the private investment vehicle, the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Reporting Persons are a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series E convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the holder's election, or automatically upon the closing of the Issuer's initial public offering, in each case based on a pre-stock split conversion price of $19.6166 per share. On July 19, 2021, the Issuer effected a one-for-3.3031 forward stock split of its common stock. The Series E convertible preferred stock has no expiration date.
F2: The Convertible Promissory Note dated as of March 17, 2021 (the "Note") will automatically convert, upon the first of the following transactions to occur, into: (i) shares of the Issuer's common stock upon a qualified initial public offering ("IPO") or a qualified merger with a Special Purpose Acquisition Issuer ("SPAC"); or (ii) shares of the Issuer's preferred stock in the event of a qualified equity financing in which the Issuer raises gross proceeds of $30 million or more through sale of preferred stock. The Note is also convertible into shares of the Issuer's capital stock issued in a non-qualifying financing transaction upon the election of the Reporting Persons (as defined below).
F3: The Note is convertible at a conversion price equal to the lower of (i) a per share price equal to 82% of the per share price paid by the new investors in such qualified financing, IPO or SPAC transaction or (ii) the price per share calculated on the basis of a pre-money valuation of the Issuer of $1.5 billion divided by the aggregate number of shares of common stock of the Issuer deemed outstanding on an as-converted, fully diluted basis including (a) all shares reserved under the Issuer's stock option plan and (b) 50% of additional shares reserved in connection with any expansion of the option pool as a result of the transaction, as of immediately prior to such qualified financing, public offering, or conversion event ("Cap Price").
F4: In the event of a non-qualified financing, the Note is convertible at the Cap Price. In the event of a deemed liquidation event, the outstanding balance may be converted into that number of shares of a new series of preferred stock of the Issuer at the Cap Price. On or after the maturity date of the Note, at the option of the Reporting Persons, the outstanding balance may be converted into that number of shares of a new preferred stock of the Issuer at the Cap Price.
F5: These securities are directly owned by a private investment vehicle managed by Redmile Group, LLC ("Redmile") and may be deemed beneficially owned by Redmile as investment manager of such private investment vehicle. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (collectively with the private investment vehicle, the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Reporting Persons are a beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RayzeBio, Inc.
Report date September 19, 2023 · Filed September 22, 2023
Jointly reported with Redmile Group, LLC, Green Jeremy
Section 16 reporting ended · disclosed 2023-09-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,857,706 |
Last balance in matching sequence
After 2023-09-19 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2023-09-19 · Conversion · Acquired 864,509 · Balance 864,509 F1: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F2: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 2 · 2023-09-19 · Conversion · Acquired 494,687 · Balance 1,359,196 F1: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F2: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 3 · 2023-09-19 · Conversion · Acquired 498,510 · Balance 1,857,706 F1: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F2: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2023-09-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-09-19 · Conversion · Disposed 864,509 · Balance 0 F1: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F2: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2023-09-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-19 · Conversion · Disposed 432,254 · Balance 0 F1: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F2: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectSee Footnote | 0 |
Reported balance
After 2023-09-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-19 · Conversion · Disposed 498,510 · Balance 0 F1: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F2: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date.
F2: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 19, 2023 Filed Sep 22, 2023 01:30 UTC | RayzeBio, Inc. RYZB · Entity 93779 | ConversionSeries D Preferred Stock · Derivative | 498,510 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-102920 · tm2326557-1_4seq1.xml · derivative · entry 6 Redmile Group, LLC · CIK 0001425738 · 10% owner Green Jeremy · CIK 0001650527 · 10% owner Redmile Biopharma Investments II, L.P. · CIK 0001772230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 498,510 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F1 · derivative.exercise_date: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F1 · derivative.expiration_date: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F2 · ownership.nature: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 19, 2023 Filed Sep 22, 2023 01:30 UTC | RayzeBio, Inc. RYZB · Entity 93779 | ConversionSeries C Preferred Stock · Derivative | 432,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-102920 · tm2326557-1_4seq1.xml · derivative · entry 5 Redmile Group, LLC · CIK 0001425738 · 10% owner Green Jeremy · CIK 0001650527 · 10% owner Redmile Biopharma Investments II, L.P. · CIK 0001772230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 494,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F1 · derivative.exercise_date: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F1 · derivative.expiration_date: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F2 · ownership.nature: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 19, 2023 Filed Sep 22, 2023 01:30 UTC | RayzeBio, Inc. RYZB · Entity 93779 | ConversionSeries B Preferred Stock · Derivative | 864,509 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-102920 · tm2326557-1_4seq1.xml · derivative · entry 4 Redmile Group, LLC · CIK 0001425738 · 10% owner Green Jeremy · CIK 0001650527 · 10% owner Redmile Biopharma Investments II, L.P. · CIK 0001772230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 864,509 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F1 · derivative.exercise_date: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F1 · derivative.expiration_date: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F2 · ownership.nature: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 19, 2023 Filed Sep 22, 2023 01:30 UTC | RayzeBio, Inc. RYZB · Entity 93779 | ConversionCommon Stock | 498,510 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-102920 · tm2326557-1_4seq1.xml · nonDerivative · entry 3 Redmile Group, LLC · CIK 0001425738 · 10% owner Green Jeremy · CIK 0001650527 · 10% owner Redmile Biopharma Investments II, L.P. · CIK 0001772230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,857,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F2 · ownership.nature: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 19, 2023 Filed Sep 22, 2023 01:30 UTC | RayzeBio, Inc. RYZB · Entity 93779 | ConversionCommon Stock | 494,687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-102920 · tm2326557-1_4seq1.xml · nonDerivative · entry 2 Redmile Group, LLC · CIK 0001425738 · 10% owner Green Jeremy · CIK 0001650527 · 10% owner Redmile Biopharma Investments II, L.P. · CIK 0001772230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,359,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F2 · ownership.nature: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| September 19, 2023 Filed Sep 22, 2023 01:30 UTC | RayzeBio, Inc. RYZB · Entity 93779 | ConversionCommon Stock | 864,509 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-23-102920 · tm2326557-1_4seq1.xml · nonDerivative · entry 1 Redmile Group, LLC · CIK 0001425738 · 10% owner Green Jeremy · CIK 0001650527 · 10% owner Redmile Biopharma Investments II, L.P. · CIK 0001772230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 864,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Series B preferred stock, Series C preferred stock and Series D preferred stock converted into shares of the Issuer's common stock automatically upon the closing of the Issuer's initial public offering for no consideration. None of the series of preferred stock had an expiration date. F2 · ownership.nature: These securities are directly owned by Redmile Biopharma Investments II, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.